Promising Result for Patients with Prurigo Nodularis: Targeting IL-4 and IL-13 Signaling
Directly from EADV 2023, Martin Metz from Charité’s Institute of Allergology in Berlin, Germany, discusses the significance of dual inhibition of IL-13 and IL-4 in prurigo nodularis.
